Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 16714293
De Chiara G, et al. (2006) Bcl-2 Phosphorylation by p38 MAPK: identification of target sites and biologic consequences. J Biol Chem 281, 21353-61 16714293
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T56-p - Bcl-2 (human)
Modsite: FSSQPGHtPHPAASR SwissProt Entrez-Gene
Orthologous residues
Bcl‑2 (human): T56‑p, Bcl‑2 (mouse): N56‑p, Bcl‑2 (rat): N56‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CESS (lymphoblastoid), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
K252a increase
SB203580 K252a inhibit treatment-induced increase

S87-p - Bcl-2 (human)
Modsite: AAAGPALsPVPPVVH SwissProt Entrez-Gene
Orthologous residues
Bcl‑2 (human): S87‑p, Bcl‑2 (mouse): S84‑p, Bcl‑2 (rat): S84‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  CESS (lymphoblastoid), MEF (fibroblast)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE P38A (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE P38A (human) phospho-antibody, pharmacological inhibitor of upstream enzyme, pharmacological activator of upstream enzyme, genetic knockout/knockin of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
K252a increase
SB203580 K252a inhibit treatment-induced increase